Skip to main content

Advertisement

SpringerLink
Log in

A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib

  • PRECLINICAL STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background The study was aim to assess the efficacy and safety of sunitinib on 14 Chinese patients with locally unresectable or metastatic Alveolar Soft Part Sarcoma (ASPS) at two institutions retrospectively. Methods Patients were treated with 37.5 mg of sunitinib once daily continuously without a scheduled off-treatment period. Dose holds or reductions were recommended for grade 3 AEs but were required for grade 4 AEs. Restarting treatment of sunitinib was allowed when AEs returned back to grade 1 or disappeared. The treatment was continued until progression disease (PD), unacceptable toxicity or death. Results From January 2011 to December 2015, 14 patients with unresectable or metastatic ASPS received sunitinib treatment. Among them, 4 patients achieved partial remission (PR), and 10 patients achieved stable disease (SD). Median progression free survival (PFS) was 41.0 months (95 % CI: 7.7 to 74.4 month). Median overall survival (OS) was not reached. The 1- and 4-year OS rates were 90.0 % and 60.0 % respectively. Two patients with primarily unresectable ASPS received complete surgical resection after neoadjuvant treatment of sunitinib. The majority of toxicities encountered were grade 1 or 2 and manageable. The most common adverse events (AEs) were bleeding (35.7 %), hair & skin color change (37.5 %) and mucositis (28.6 %). Conclusions Sunitinib is effective in locally unresectable or metastatic ASPS with a good safety profile. Neoadjuvant treatment with sunitinib improves the chance of resection for patients with locally advanced ASPS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Portera CA Jr., Ho V, Patel SR, Hunt KK, Feig BW, Respondek PM, Yasko AW, Benjamin RS, Pollock RE, Pisters PW (2001) Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer 91(3):585–591

    Article  PubMed  Google Scholar 

  2. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, Healey JH, Ueda T, Yoshikawa H, Meloni-Ehrig A, Sorensen PH, Mertens F, Mandahl N, van den Berghe H, Sciot R, Dal Cin P, Bridge J (2001) The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 20(1):48–57

    Article  CAS  PubMed  Google Scholar 

  3. Ogose A, Yazawa Y, Ueda T, Hotta T, Kawashima H, Hatano H, Morita T (2003) Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. Oncology 65(1):7–13

    Article  PubMed  Google Scholar 

  4. Reichardt P, Lindner T, Pink D, Thuss-Patience PC, Kretzschmar A, Dorken B (2003) Chemotherapy in alveolar soft part sarcomas. What do we know? Eur J Cancer 39(11):1511–1516

    Article  CAS  PubMed  Google Scholar 

  5. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25(7):884–896

    Article  CAS  PubMed  Google Scholar 

  6. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368(9544):1329–1338

    Article  CAS  PubMed  Google Scholar 

  8. Demetri GD, Garrett CR, Schoffski P, Shah MH, Verweij J, Leyvraz S, Hurwitz HI, Pousa AL, Le Cesne A, Goldstein D, Paz-Ares L, Blay JY, McArthur GA, Xu QC, Huang X, Harmon CS, Tassell V, Cohen DP, Casali PG (2012) Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 18(11):3170–3179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Horsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364(6):501–513

    Article  CAS  PubMed  Google Scholar 

  10. George S, Merriam P, Maki RG, Van den Abbeele AD, Yap JT, Akhurst T, Harmon DC, Bhuchar G, O'Mara MM, D'Adamo DR, Morgan J, Schwartz GK, Wagner AJ, Butrynski JE, Demetri GD, Keohan ML (2009) Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol 27(19):3154–3160

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Stacchiotti S, Negri T, Zaffaroni N, Palassini E, Morosi C, Brich S, Conca E, Bozzi F, Cassinelli G, Gronchi A, Casali PG, Pilotti S (2011) Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. Ann Oncol 22(7):1682–1690

    Article  CAS  PubMed  Google Scholar 

  12. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, Martens M, van den Borne B, Cole P, Sciot R, Dumez H, Silberman S, Mortelmans L, van Oosterom A (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 39(14):2012–2020

    Article  CAS  PubMed  Google Scholar 

  13. Choi H (2005) Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 7(4):307–311

    Article  PubMed  Google Scholar 

  14. Lazar AJ, Das P, Tuvin D, Korchin B, Zhu Q, Jin Z, Warneke CL, Zhang PS, Hernandez V, Lopez-Terrada D, Pisters PW, Pollock RE, Lev D (2007) Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res 13(24):7314–7321

    Article  CAS  PubMed  Google Scholar 

  15. Kummar S, Allen D, Monks A, Polley EC, Hose CD, Ivy SP, Turkbey IB, Lawrence S, Kinders RJ, Choyke P, Simon R, Steinberg SM, Doroshow JH, Helman L (2013) Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 31(18):2296–2302

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Wagner AJ, Goldberg JM, Dubois SG, Choy E, Rosen L, Pappo A, Geller J, Judson I, Hogg D, Senzer N, Davis IJ, Chai F, Waghorne C, Schwartz B, Demetri GD (2012) Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer 118(23):5894–5902

    Article  CAS  PubMed  Google Scholar 

  17. Kollmannsberger C, Soulieres D, Wong R, Scalera A, Gaspo R, Bjarnason G (2007) Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects. Can Urol Assoc J 1(2 Suppl):S41–S54

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Chu TF, Rupnick MA, Kerkela R, Dallabrida SM, Zurakowski D, Nguyen L, Woulfe K, Pravda E, Cassiola F, Desai J, George S, Morgan JA, Harris DM, Ismail NS, Chen JH, Schoen FJ, Van den Abbeele AD, Demetri GD, Force T, Chen MH (2007) Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 370(9604):2011–2019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Folpe AL, Deyrup AT (2006) Alveolar soft-part sarcoma: a review and update. J Clin Pathol 59(11):1127–1132

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Lieberman PH, Foote FW Jr., Stewart FW, Berg JW (1966) Alveolar soft-part sarcoma. JAMA 198(10):1047–1051

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the patients who shared their experiences with our oncologists, as well as the network of investigators. In particular, we would like to acknowledge Yunhua Lu for helping us with data collection.

Authors’s contribution

LZG and WCM made contributions to the conception, design and analysis of data. LT and LW carried out most of the data collection and drafted the main manuscript. LZG, WCM, WHJ and ZSJ revised the manuscript. AK and ZXW discussed the data. All authors have read and approved the manuscript for publication.

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China

    Ting Li, Huijie Wang, Xiaowei Zhang & Zhiguo Luo

  2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China

    Ting Li, Huijie Wang, Xiaowei Zhang, Zhiguo Luo & Chunmeng Wang

  3. Department of Medical Oncology, Kashgar Prefecture Second People’s Hospital, XinJiang, China

    Lei Wang, Shujuan Zhang,  Atikan·Kawuli & Zhiguo Luo

  4. Department of Gastric Cancer and Soft Tissue Sarcomas, Fudan University Shanghai Cancer Center, Shanghai, China

    Chunmeng Wang

Authors
  1. Ting Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huijie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shujuan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Atikan·Kawuli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiaowei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zhiguo Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chunmeng Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Zhiguo Luo or Chunmeng Wang.

Ethics declarations

Conflict interests

The authors declare that they have no competing interests.

Funding

None.

Ethical approval

For this type of study formal consent is not required.

Additional information

Ting Li and Lei Wang contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Li, T., Wang, L., Wang, H. et al. A retrospective analysis of 14 consecutive Chinese patients with unresectable or metastatic alveolar soft part sarcoma treated with sunitinib. Invest New Drugs 34, 701–706 (2016). https://doi.org/10.1007/s10637-016-0390-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-016-0390-3

Keywords

Search

Navigation